Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Type II secretory phospholipase A2 and prognosis in patients with stable coronary heart disease: mendelian randomization study.

PloS one - 1 Jan 2011

Breitling Lutz P, Koenig Wolfgang, Fischer Marcus, Mallat Ziad, Hengstenberg Christian, Rothenbacher Dietrich, Brenner Hermann

Abstract excerpt

BACKGROUND: Serum type II secretory phospholipase A(2) (sPLA(2)-IIa) has been found to be predictive of adverse outcomes in patients with stable coronary heart disease. Compounds targeting sPLA(2)-IIa are already under development. This study investigated if an association of sPLA(2)-IIa with secondary cardiovascular disease (CVD) events may be of causal nature or mainly a matter of confounding by correlated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cardiovascular Diseases

Share to Cohort Studies

Share to Coronary Disease

Share to Follow-Up Studies

Share to Mendelian Randomization Analysis

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 21799821
DOI: 10.1371/journal.pone.0022318
PMCID: PMC3142130

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Type II secretory phospholipase A2 and prognosis in patients with stable coronary heart disease: mendelian randomization study.PMID 21799821Read ↗

Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study.Semantic proximity Read ↗

The association of PLA2G2A single nucleotide polymorphisms with type IIa secretory phospholipase A2 level but not its activity in patients with stable coronary heart disease.Semantic proximity Read ↗

Deciphering the Causal Role of sPLA2s and Lp-PLA2 in Coronary Heart DiseaseSemantic proximity Read ↗

Molecular and functional characterization of polymorphisms in the secreted phospholipase A2 group X gene: relevance to coronary artery disease.Semantic proximity Read ↗

Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels.Semantic proximity Read ↗

PLA2G10 Gene Variants, sPLA2 Activity, and Coronary Heart Disease Risk.Semantic proximity Read ↗

Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study.Semantic proximity Read ↗

Lp-PLA2, scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease.Semantic proximity Read ↗

Lipoprotein-associated phospholipase A2 single-nucleotide polymorphisms and cardiovascular events in patients with coronary artery disease.Semantic proximity Read ↗

The GPIIIA PlA2 polymorphism is associated with an increased risk of cardiovascular adverse events.Semantic proximity Read ↗

Association of PLA2G4A with myocardial infarction is modulated by dietary PUFAs.Semantic proximity Read ↗

Functional analysis of two PLA2G2A variants associated with secretory phospholipase A2-IIA levels.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.